3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
4
Phase 3
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Carcinoma, Hepatocellular
8
Nasopharyngeal Carcinoma
7
Recurrence
6
Neoplasms
6
Esophageal Neoplasms
6
Breast Neoplasms
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Esophageal Squamous Cell Carcinoma
5
Colorectal Neoplasms
5
Locally Advanced Rectal Cancer
4
Carcinoma, Renal Cell
4
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Rectal Neoplasms
3
Melanoma
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Hyperthermia
2
Chondrosarcoma
2
Carcinoma, Transitional Cell
2
Interventions
Carboplatin
79
pembrolizumab
64
Paclitaxel
64
Cyclophosphamide
47
Capecitabine
34
Doxorubicin
31
Taxes
28
130-nm albumin-bound paclitaxel
28
Albumin-Bound Paclitaxel
27
Gemcitabine
20
atezolizumab
18
Epirubicin
18
Cisplatin
18
Bevacizumab
18
olaparib
17
sacituzumab govitecan
15
Docetaxel
15
eribulin
14
toripalimab
13
durvalumab
13
camrelizumab
13
Drug Therapy
12
apatinib
9
Trastuzumab
9
Radiotherapy
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Biopsy
8
tislelizumab
7
talazoparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Triple Negative Breast Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06802757
2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2
Recruiting
72 enrolled